Contact Us

Future of Tech

Recapping our Exclusive Symposium with Dr Adam Fremeth, From Ivey Business School

2024, 2025, AI, Business, Community, Economics, Employee Benefits, Equity in workplace, Exclusive Data, Executive Team, Finance, Future of Tech, Hiring, human resources, Industry Partners, Ivey Business, Leadership, Network, Policies, Research and Resources, Thought Leadership, Uncategorized / By

As part of our ongoing commitment to providing businesses with actionable insights, the 2024 Benchmark Symposium offered valuable perspectives on the economic outlook for the coming year. Aimed at helping businesses navigate uncertainty and plan strategically, this year’s presentation by Ivey Business School Professor Adam Fremeth provided a high-level overview of critical trends that will …

Recapping our Exclusive Symposium with Dr Adam Fremeth, From Ivey Business School Read More »

Understanding The Impact Of Industry 5.0 by Gisela Carere, MBA

AI, Business, Community, Exclusive Data, Executive Team, Forbes, Future of Tech, human resources, Industry Partners, Leadership, Research and Resources, Thought Leadership, Uncategorized / By

The next phase of the industrial revolution, Industry 5.0, is upon us. Throughout the last four industrial revolutions, breakthroughs from penicillin to the microwave to the internet fundamentally changed and shaped healthcare and society, respectively. I believe that recognizing and unlocking the potential of those “eureka” moments is true cognitive efficiency at play. Embracing The …

Understanding The Impact Of Industry 5.0 by Gisela Carere, MBA Read More »

Canada’s Biosimilar Revolution Continues

2024, Chronic Illness, Employee Benefits, Federal, Future of Tech, Group Benefits, Health and Wellness, Healthcare, human resources, Insurance, Medication, Research and Resources, Thought Leadership / By

Delving deeper into the promising landscape shaped by Ontario’s innovative biosimilar regulations. Discover how these policies are fostering enhanced accessibility for patients and driving positive transformations in the pharmaceutical industry.   There are a few similarities and a few differences between biosimilars and generic drugs. A generic drug is an exact copy of its reference …

Canada’s Biosimilar Revolution Continues Read More »

Get the latest updates

Newsletter signup
This field is for validation purposes and should be left unchanged.

Links

Support

© 2024 Benchmark Benefit Solutions Inc. All rights reserved.

Instagram Linkedin Facebook Youtube
Scroll to Top